No Carolina / NY / Florida
Ph: 561.316.3330

MicroCare Acquires Certol International: Expands Products and Services

Editor: What To Know

  • MicroCare, LLC a global supplier of critical cleaning fluids and materials used in the electronics, medical device manufacturing, fiber optic and metal finishing markets announced today that it has acquired Certol International, a Denver, Colorado based manufacturer of specialty cleaning and disinfecting products to the medical, dental, and consumer marketplaces.
  •   The Certol leading product and development initiatives will amplify the already strong programs in the MicroCare pipeline and will enable continued focus on high growth segments, such as automotive, medical, electronics and fiber optic communications.
  • location will reinforce our position as a leading supplier to the industries we serve, and will allow us to more efficiently deliver an expanded range of complementary solutions to our customers.

MicroCare, LLC a global supplier of critical cleaning fluids and materials used in the electronics, medical device manufacturing, fiber optic and metal finishing markets announced today that it has acquired Certol International, a Denver, Colorado based manufacturer of specialty cleaning and disinfecting products to the medical, dental, and consumer marketplaces.

“We are very excited to announce this acquisition.  Certol has a 40-year history of providing EPA registered high performance surface disinfectants and specialty cleaners engineered for use.

in dental offices, medical offices, and hospital settings. Certol also manufactures specialty products used in industrial, marine and consumer cleaning applications,” said Tom Tattersall, Chief Executive Officer at MicroCare.

“We believe that the Certol product lines, customer relationships, and centralized U.S. location will reinforce our position as a leading supplier to the industries we serve, and will allow us to more efficiently deliver an expanded range of complementary solutions to our customers.  With this acquisition, MicroCare will continue to be well-situated to capitalize on the many emerging trends in the dental and medical markets.  We view this important acquisition as an excellent step to position the business for continued growth as we work with customers to solve their cleaning and disinfecting challenges.”

Certol International

This acquisition is aligned with the MicroCare strategic goals and priorities, namely, to fuel growth through the delivery of innovative, value-added solutions and services into the global critical cleaning industry.  The Certol leading product and development initiatives will amplify the already strong programs in the MicroCare pipeline and will enable continued focus on high growth segments, such as automotive, medical, electronics and fiber optic communications.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy